Regenerative Therapie von Sehnen- und Banderkrankungen bei Pferden

F. Geburek; P. Stadler

doi:10.1055/s-0038-1623088

Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere, Table of Contents

Tierarztl Prax Ausg G Grosstiere Nutztiere 2011; 39(06): 373-383
DOI: 10.1055/s-0038-1623088

Übersichtsartikel

Schattauer GmbH

Regenerative Therapie von Sehnen- und Banderkrankungen bei Pferden

Terminologie, Herstellung, biologisches Potenzial und In-vitro-EffekteRegenerative therapy for tendon and ligament disorders in horses. Terminology, production, biologic potential and in vitro effects

F. Geburek

,

P. Stadler

Abstract

Zusammenfassung

Herkömmliche Therapieansätze führen bei Pferden zu einer unbefriedigenden Sehnenheilung mit einer relativ hohen Rezidivrate. Deshalb werden seit einigen Jahren unter anderem in vitro und an Labortieren so genannte regenerative Therapieformen wissenschaftlich untersucht. Darunter wird der Einsatz von Substanzen verstanden, die idealerweise die Bildung eines Ersatzgewebes bewirken, das vergleichbare funktionelle Eigenschaften hat wie das Ursprungsgewebe und sich somit von minderwertigerem Narbengewebe abhebt. Derzeit ist eine Fülle verschiedener Substrate entweder kommerziell verfügbar oder mithilfe von „Kits“ unter Praxisbedingungen herstellbar. Es werden die wesentlichen Erkenntnisse zur Herstellung und zum regenerativen Potenzial von kernhaltigen Zellen bzw. Stammzellen aus Knochenmark und Fettgewebe sowie der Blutprodukte PRP (thrombozytenreiches Plasma), ACP (autologes konditioniertes Plasma), ACS (autologes konditioniertes Serum) und der Gerüstsubstanz UBM (urinary bladder matrix) vorgestellt. Zuletzt wird das Potenzial einzelner Wachstumsfaktoren und der Gentherapie beleuchtet. Bisher wird angenommen, dass die Regeneration von Sehnengewebe durch ein komplexes Zusammenspiel aus Gerüstsubstanzen, Wachstumsfaktoren und Zellen begünstigt wird. Es sind bislang nur wenige Untersuchungen verfügbar, die einen Vergleich zwischen den genannten Substanzen erlauben. Untersuchungen zur Wirkung der Substrate an lebenden Pferden werden an anderer Stelle vorgestellt.

Summary

Conventional treatments of equine tendon injuries lead to an unsatisfactory healing process that usually results in a relatively high recurrence rate. Therefore, in recent years so-called regenerative therapeutics were studied scientifically in vitro and in laboratory animals. These include substances that ideally lead to the formation of replacement tissue, which in contrast to the low quality scar, has similar functional properties as the original intact tendon. Currently, a plethora of different substrates is either commercially available or can be produced in practice with the help of kits. The current knowledge on the production and the regenerative potential of nucleated cells like stem cells from bone marrow and fat tissue, of the blood products PRP (platelet rich plasma), ACP (autologous conditioned plasma), ACS (autologous conditioned serum) and of the scaffold substance UBM (urinary bladder matrix) are presented. Finally, the potential of some growth factors and of gene therapy is considered. Currently, it is assumed that the regeneration of tendon tissue is promoted by a complex interaction of scaffolds, growth factors and cells. At present, only very few studies are available which allow a comparison between these substances. Studies on the effect of regenerative substrates on tendons in live horses are presented elsewhere.

Schlüsselwörter

Pferd - Sehne - Fesselträger - Stammzellen - PRP - ACS - ACP - UBM

Key words

Horse - tendon - suspensory ligament - stem cell - PRP - ACS - ACP - UBM

Full Text

References

Literatur
1 Arnhold SJ, Goletz I, Klein H, Stumpf G, Beluche LA, Rohde C, Addicks K, Litzke LF. Isolation and characterization of bone marrow-derived equine mesenchymal stem cells. Am J Vet Res 2007; 68: 1095-1105.
2 Arnhold S, Müller M, Raabe O, Addicks K, Wenisch S. Einfluss nichtsteroidaler Antiphlogistika auf equine mesenchymale Stammzellen in vitro. Tierärztl Prax 2010; 38 (G): 37-46.
3 Arnoczky SR, Lavagnino M, Egerbacher M, Caballero O, Gardner K. Matrix Metalloproteinase Inhibitors Prevent a Decrease in the Mechanical Properties of Stress-Deprived Tendons. An In Vitro Experimental Study. Am J Sports Med 2007; 35: 763-769.
4 Baltzer AWA, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthr Cartilage 2009; 17: 152-160.
5 Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal Stromal Cells. A Novel Treatment Modality for Tissue Repair. Hematopoietic Stem Cells VII: Ann N Y Acad Sci 2009; 1176: 101-117.
6 Birch HL, Worboys S, Eissa S, Jackson B, Strassburg S, Clegg PD. Matrix metabolism rate differs in functionally distinct tendons. Matrix Biol 2008; 27: 182-189.
7 Bosch G. Towards a staged evidence based approach for the treatment of tendon injuries in the horse. [PhD Dissertation] Utrecht, the Netherlands: Faculty of Veterinary Medicine. Utrecht University; 2009
8 Bosch G, van Weeren PR, Barneveld A, van Schie HTM. Computerised analysis of standardised ultrasonographic images to monitor the repair of surgically created core lesions in equine superficial digital flexor tendons after intratendinous platelet rich plasma or placebo. Vet J. 2009 doi:
9 Bosch G, van Schie HTM, de Groot MW, Cadby JA, van de Lest CHA, Barneveld A, van Weeren PR. Effects of Platelet-Rich Plasma on the Quality of Repair of Mechanically Induced Core Lesions in Equine Superficial Digital Flexor Tendons: A Placebo-Controlled Experimental Study. J Orthop Res 2010; 28 (02) 211-217.
10 Brehm W. Erfahrungen mit der Stammzell-Therapie von Sehnenläsionen beim Pferd. In: Vortragsband des BPT-Kongress 2008, Hannover. 13.-16. November BPT Akademie GmbH; Frankfurt: 2008: 20-26.
11 Brennan EP, Reing J, Chew D, Myers-Irvin JM, Young EJ, Badylak SF. Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix. Tissue Eng 2006; 12: 1249-2955.
12 Burmester GR, Grifka J. Neufassungen der Empfehlungen der Kommission Pharmakotherapie der DGRh. Stellungnahme zum Einsatz von Orthokin. Z Rheumatol 2007; 66: 83-84.
13 Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084.
14 Colleoni S, Donofrio G, Lagutina I, Duchi R, Galli C, Lazzari G. Establishment, differentiation, electroporation, viral transduction, and nuclear transfer of bovine and porcine mesenchymal stem cells. Cloning Stem Cells 2005; 7 (03) 154-166.
15 Colleoni S, Bottani E, Tessaro I, Mari G, Merlo B, Romagnoli N, Spadari A, Galli C, Lazzari G. Isolation, growth and differentiation of equine mesenchymal stem cells: effect of donor, source, amount of tissue and supplementation with basic fibroblast growth factor. Vet Res Commun 2009; 33 (08) 811-821.
16 Conrad S, Nufer F, Mundle K, Ihring J, Seid K, Walliser U, Skutella T. Mesenchymale Stammzellen aus dem Fettgewebe des Pferdes – Isolation Expansion und Charakterisierung. In: Vortragszusammenfassungen der XVIII. Tagung über Pferdekrankheiten im Rahmen der Equitana, Essen. 21.-22. März 2009 wak Verlag GmbH; Gescher: 2009: 119.
17 Crovace A, Lacitignola L, Rossi G, Francioso E. Histological and Immunohistochemical Evaluation of Autologous Cultured Bone Marrow Mesenchymal Stem Cells and Bone Marrow Mononucleated Cells in Collagenase-Induced Tendinitis of Equine Superficial Digital Flexor Tendon. Vet Med Int. 2010 in press. doi:
18 Dahlgren LA, van der Meulen MCH, Bertram JEA, Starrak GS, Nixon AJ. Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis. J Orthop Res 2002; 20: 910-919.
19 Dahlgren LA. Fat derived mesenchymal stem cells for equine tendon repair. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S14.
20 Dahlgren LA. Management of Tendon Injuries. In: Current Therapy in Equine Medicine. 6th ed.. Robinson NE, Sprayberry KA. eds. St. Louis: Saunders, Elsevier; 2009: 518-523.
21 Del Bue M, Riccò S, Conti V, Merli E, Ramoni R, Grolli S. Platelet lysate promotes in vitro proliferation of equine mesenchymal stem cells and tenocytes. Vet Res Commun 2007; 31 (Suppl. 01) 289-292.
22 Del Bue M, Riccò S, Ramoni R, Conti V, Gnudi G, Grolli S. Equine adipose tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo . Vet Res Commun 2008; 32 (Suppl. 01) S51-S55.
23 De Mos M, van der Windt AE, Jahr H, van Schie HT, Weinans H, Verhaar JA, van Osch GJ. Can platelet rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008; 36: 1171-1178.
24 De Schauwer C, Meyer E, Van de Walle GR, Van Soom A. Markers of stemness in equine mesenchymal stem cells: a plea for uniformity. Theriogenology 2011; 75 (08) 1431-1443.
25 Durando MM, Zarucco L, Schaer TP, Ross M, Reef VB. Pneumopericardium in a horse secondary to sternal bone marrow aspiration. Equine Vet Educ 2006; 18: 75-79.
26 Durgam SS, Stewart AA, Caporali EH, Karlin WM, Stewart MC. Effect of tendon-derived progenitor cells on a collagenase-induced model of tendinitis in horses. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S27.
27 Dyson S. Medical management of superficial digital flexor tendonitis: a comparative study in 219 horses (1992–2000). Equine Vet J 2004; 36: 415-419.
28 Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-1508.
29 Everts PAM, Hoffmann J, Weibrich G, Mahoney CB, Schönberger PAM, van Zundert A, Knape JTA. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfusion Medicine 2006; 16: 363-368.
30 Fibbe WE. Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci 2007; 1106: 272-278.
31 Fortier LA. Stem Cells: Classifications, Controversies, and Clinical Applications. Vet Surg 2005; 34: 415-423.
32 Fortier LA, Smith RK. Regenerative medicine for tendinous and ligamentous injuries of sport horses. Vet Clin North Am Equine Pract 2008; 24: 191-201.
33 Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290-296.
34 Frisbie DD, Smith RKW. Clinical update on the use of mesenchymal stem cells in equine orthopedics. Equine Vet J 2010; 42: 86-89.
35 Grimm J, Kircher MF, Weissleder R. Cell tracking. Prinzipien und Anwendung. Radiologe 2007; 47: 25-33.
36 Guest DD, Smith MR, Allen WR. Monitoring the fate of autologous and allogenic progenitor cells injected into the superficial digital flexor tendon of horses: Preliminary study. Equine Vet J 2008; 40: 178-181.
37 Guest DJ, Smith MRW, Allen MR. Equine embryonic stem-like cells and mesenchymal stromal cells have different survival rates and migration patterns following their injection into damaged superficial digital flexor tendon. Equine Vet J 2010; 42: 636-642.
38 Guest D, Li X, Allen W. Establishing an equine embryonic stem cell line. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S18.
39 Herthel D. Clinical use of stem cells and marrow components to stimulate suspensory ligament regeneration. In: Diagnosis and Management of Lameness in the Horse. Ross MW, Dyson SJ. eds. Philadelphia: Saunders; 2003: 673-674.
40 James SL, Ali K, Pocock C, Robertson C, Walter J, Bell J, Connell D. Ultrasound guided dry needling and autologous blood injection for patellar tendinosis. Br J Sports Med 2007; 41: 518-521.
41 Kissich C, Böttcher P, Gottschalk J, Brehm W, Ionita JC. Biochemische Eigenschaften des equinen Autologous Conditioned Plasma^TM . In: Dtsch. Vet. Med. Gesellsch (Hrsg.): 20. Arbeitstagung der Fachgruppe „Pferdekrankheiten“, Hannover. 29.2.-1.3.2010 Gießen: DVG-Service GmbH; 2010: 60.
42 Klein MB, Yalamanchi N, Pham H, Lonaker T, Chang J. Flexor tendon healing in vitro: effects of TGF-beta on tendon cell collagen production. J Hand Surg [Am] 2002; 27: 615-620.
43 Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol 2007; 7: 26.
44 Koch TG, Berg LC, Betts DH. Concepts for the clinical use of stem cells in equine medicine. Can Vet J 2008; 49: 1009-1017.
45 Koch TG, Berg LC, Betts DH. Current and future regenerative medicine – principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine. Can Vet J 2009; 50: 155-665.
46 Koerner J, Nesic D, Romero JD, Brehm W, Mainil-Varlet P, Grogan SP. Equine peripheral blood-derived progenitors in comparison to bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 1613-1619.
47 Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103: 696-709.
48 Leppänen M, Miettinen S, Mäkinen S, Wilpola P, Katiskalahti T, Heikkilä P, Tulamo RM. Management of equine tendon & ligament injuries with expanded autologous adipose derived mesenchymal stem cells: a clincal study. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S21.
49 Lutz S, Jahn W, Sill V, Pokar J, Jaek F, Brehm W. Vergleich der intraläsionalen Behandlung von Fesselträgerläsionen mit thrombozytenangereichertem Plasma (PRP) und xenogener, azellulärer Matrix (ACell^®). In: Dtsch. Vet. Med. Gesellsch. (Hrsg.): 20. Arbeitstagung der Fachgruppe „Pferdekrankheiten“, Hannover. 29.2.-1.3.2010 Gießen: DVG-Service GmbH; 2010: 61.
50 Majewski M, Ochsner P, Fangjun Liu, Flueckiger R, Evans C. Achilles tendon healing by autologous conditioned serum. Posterpräsentation im Rahmen des 9th Congress of the European Federation of National Associations of Orthopedics and Traumatology. Nizza, Frankreich: 29. Mai.-1. Juni 2008. Abstract P1283.
51 Molloy T, Wang Y, Murrell GAC. The Roles of Growth Factors in Tendon and Ligament Healing. Sports Med 2003; 33 (05) 381-394.
52 Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose derived nucleated cell fractions on tendon repair in horses with collagenaseinduced tendinitis. Am J Vet Res 2008; 69: 928-937.
53 Oedayrajsingh Varma MJ, Breuls RGM, Schouten TE, Jurgens WJFM, Bontkes HJ, Schuurhuis GJ, van Ham SM, van Milligen FJ. Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev 2007; 16: 91-104.
54 Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F, Petrini M. Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses. Tissue Eng 2007; 13: 2949-2955.
55 Paris DBBP, Stout TAE. Equine embryos and embryonic stem cells: Defining reliable markers of pluripotency. Theriogenology 2010; 74: 516-524.
56 Pasternak B, Aspenberg P. Metalloproteinase and their inhibitors – diagnostic and therapeutic opportunities in orthopedics. Acta Orthopaedica 2009; 80: 693-703.
57 Radcliffe CH, Fortier LA. Development of a patient-side construct for cartilage regeneration using mesenchymal stem cells and platelet rich plasma composite grafts generated through simple centrifugation techniques. Proceedings of the ACVS Symposium, 5.-7.10. 2006; Washington DC, USA Vet Surg 2006; 35 (06) E21-22.
58 Ramirez JUC. Use of autologous platelet concentrates for the treatment of musculosceletal injuries in the horse. [PhD Dissertation] Bellaterra, Spanien: Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, Universitat Autonoma Barcelona; 2006
59 Reed SA, Johnson SE. Equine Umbilical Cord Blood Contains a Population of Stem Cells That Express Oct4 and Differentiate Into Mesodermal and Endodermal Cell Types. J Cell Physiol 2008; 215: 329-336.
60 Ribitsch I, Burj J, Gittel C, Brehm W. Umbilical cord blood & umbilical cord matrix: a comparison of two potential mesenchymal stem cell sources. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S24.
61 Richardson LE, Duhia J, Clegg PD, Smith R. Stem cells in veterinary medicine – attempts at regenerating equine tendon after injury. Trends Biotechnol 2007; 25: 409-416.
62 Sanchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices. Am J Sports Med 2007; 35: 245-251.
63 Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE, Kornatowski MA, Nixon AJ. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. J Orthop Res 2009; 27 (10) 1392-1398.
64 Schnabel LV, Mohammed HO, Miller BJ, McDermott WG, Jacobson MS, Santangelo KS, Fortier LA. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 2007; 25: 230-240.
65 Schnabel LV, Sonea HO, Jacobson MS, Fortier LA. Effects of platelet rich plasma (PRP) and acellular bone marrow on gene expression patterns and DNA content of equine suspensory ligament explant cultures. Equine Vet J 2008; 40: 260-265.
66 Smith JJ, Ross MW, Smith RK. Anabolic effects of acellular bone marrow, platelet rich plasma, and serum on equine suspensory ligament fibroblasts in vitro. Vet Comp Orthop Traumatol 2006; 19: 43-47.
67 Smith RK. Mesenchymal stem cell therapy for equine tendinopathy. Disabil Rehabil 2008; 30: 1752-1758.
68 Smith RKW. Principles of stem cell therapy in the horse – the science behind the technology. Pferdeheilk 2008; 24: 508-512.
69 Smith RKW. Stem cell therapy for tendon and ligament injuries in the horse – technique and outcome. Pferdeheilk 2008; 24: 513-518.
70 Staszyk C, Mensing N, Hambruch N, Häger JD, Pfarrer C, Gasse H. Equine periodontal ligament: a source of mesenchymal stem cells for regenerative therapies in the horse?. Regenerative Medicine 2009; 4 (06) (Suppl. 02) S26.
71 Stewart AA, Barrett JG, Byron CR, Yates AC, Durgam SS, Evans RB, Stewart MC. Comparison of equine tendon-, muscle- and bone marrow-derived cells cultured on tendon matrix. Am J Vet Res 2009; 70: 750-757.
72 Souza MV, van Weeren PR, van Schie HTM, van de Lest CHA. Regional differences in biochemical, biomechanical and histomorphological characteristics of the equine suspensory ligament. Equine Vet J 2010; 42: 611-620.
73 Sun HB, Yonghui L, Fung DT, Majeska RJ, Schaffler MB, Flatow EL. Coordinate Regulation of Il-1β and MMP-13 in Rat Tendons Following Subrupture Fatigue Damage. Clin Orthop Rel Res 2008; 466: 1555-1561.
74 Suresh SP, Ali KE, Jones H, Connell DA. Medial epicondylitis: is ultrasound guided autologous blood injection an effective treatment?. Br J Sports Med 2006; 40: 935-939.
75 Taylor MA, Norman TL, Clovis NB, Blaha JD. The response of rabbit patella tendons after autologous blood injection. Med Sci Sports Exerc 2002; 25: 70-73.
76 Taylor SE, Smith RK, Clegg PD. Mesenchymal stem cell therapy in equine musculosceletal disease: scientific fact or clinical fiction?. Equine Vet J 2007; 39: 172-180.
77 Thorpe CT, Clegg PD, Birch HL. A review of tendon injury. Why is the equine superficial flexor tendon most at risk?. Equine Vet J 2010; 42: 174-180.
78 Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesenchymal stromal cells: adipogenic and osteogenic capacity. Vet Surg 2006; 35: 601-610.
79 Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg 2007; 36: 613-622.
80 Violini S, Ramelli P, Pisani LF, Gorni C, Mariani P. Horse bone marrow mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic differentiation by in vitro exposure to BMP-12. BMC Cell Biol. 2009 Apr 22 10. 29 doi:
81 Waselau M, Sutter WW, Genovese RL, Bertone AL. Intralesional injection of platelet-rich-plasma followed by controlled exercise for treatment of mid-body suspensory ligament desmitis in Standardbred racehorses. J Am Vet Med Assoc 2008; 232: 1515-1520.
82 Weinberger T. Klinische Erfahrungen mit der Anwendung von ACS/ORTHOKIN/IRAP beim Pferd. Pferde Spiegel 2008; 11: 111-115.
83 Wright-Carpenter T, Klein P, Schäferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25: 588-593.
84 Wright-Carpenter T, Opolon P, Appell HJ, Meijer H, Wehling P, Mir LM. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med 2004; 25: 582-587.
85 Young RG, Butler DL, Weber W, Caplan AI, Gordon Sl, Fink DJ. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orth Res 1998; 16: 406-413.